Concepts (79)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sphincter of Oddi Dysfunction | 6 | 2017 | 48 | 1.180 |
Why?
|
| Abdominal Pain | 4 | 2017 | 97 | 0.890 |
Why?
|
| Brain Injuries, Traumatic | 4 | 2021 | 105 | 0.610 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2016 | 9 | 0.570 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2016 | 9 | 0.570 |
Why?
|
| Hyperglycemia | 3 | 2022 | 158 | 0.530 |
Why?
|
| Progesterone | 4 | 2021 | 115 | 0.530 |
Why?
|
| Sphincterotomy, Endoscopic | 4 | 2017 | 79 | 0.520 |
Why?
|
| Cholecystectomy | 4 | 2017 | 79 | 0.450 |
Why?
|
| Sphincter of Oddi | 3 | 2017 | 51 | 0.410 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 5 | 2017 | 348 | 0.380 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 2 | 2021 | 15 | 0.380 |
Why?
|
| Spectrin | 2 | 2021 | 17 | 0.380 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2021 | 23 | 0.370 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2021 | 92 | 0.360 |
Why?
|
| Common Bile Duct Diseases | 2 | 2016 | 24 | 0.270 |
Why?
|
| Pain, Postoperative | 2 | 2017 | 214 | 0.260 |
Why?
|
| Pancreatitis | 3 | 2016 | 279 | 0.260 |
Why?
|
| Emergency Medical Services | 2 | 2018 | 225 | 0.250 |
Why?
|
| Stroke | 3 | 2022 | 2161 | 0.240 |
Why?
|
| Insulins | 1 | 2022 | 5 | 0.220 |
Why?
|
| Intubation, Intratracheal | 2 | 2018 | 99 | 0.180 |
Why?
|
| Insulin | 2 | 2022 | 617 | 0.180 |
Why?
|
| Goals | 1 | 2019 | 65 | 0.170 |
Why?
|
| Glasgow Coma Scale | 1 | 2018 | 65 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2016 | 1615 | 0.160 |
Why?
|
| Analgesia | 1 | 2017 | 58 | 0.150 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 361 | 0.140 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 317 | 0.140 |
Why?
|
| Middle Aged | 10 | 2021 | 21119 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 693 | 0.140 |
Why?
|
| Pain Management | 1 | 2017 | 186 | 0.130 |
Why?
|
| Adult | 10 | 2021 | 21375 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2019 | 7028 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 378 | 0.130 |
Why?
|
| Prospective Studies | 5 | 2022 | 3702 | 0.110 |
Why?
|
| Male | 11 | 2021 | 37281 | 0.110 |
Why?
|
| Female | 11 | 2021 | 38015 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2016 | 1341 | 0.100 |
Why?
|
| Humans | 14 | 2022 | 68525 | 0.100 |
Why?
|
| Young Adult | 5 | 2021 | 5708 | 0.090 |
Why?
|
| Manometry | 3 | 2015 | 276 | 0.090 |
Why?
|
| Biomarkers | 2 | 2021 | 1593 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 1465 | 0.060 |
Why?
|
| Insulin, Regular, Human | 1 | 2022 | 4 | 0.050 |
Why?
|
| United States | 3 | 2022 | 7335 | 0.050 |
Why?
|
| Progestins | 1 | 2021 | 19 | 0.050 |
Why?
|
| Prognosis | 2 | 2017 | 2093 | 0.050 |
Why?
|
| Neuroglia | 1 | 2021 | 136 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 303 | 0.050 |
Why?
|
| Cell Death | 1 | 2021 | 329 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2019 | 87 | 0.040 |
Why?
|
| Glasgow Outcome Scale | 1 | 2019 | 15 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 334 | 0.040 |
Why?
|
| Hypoglycemia | 1 | 2019 | 72 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 631 | 0.040 |
Why?
|
| Aged | 3 | 2019 | 14842 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 219 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 4843 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 197 | 0.040 |
Why?
|
| Transportation of Patients | 1 | 2017 | 46 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 296 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 377 | 0.030 |
Why?
|
| Neurons | 1 | 2021 | 881 | 0.030 |
Why?
|
| Pressure | 1 | 2015 | 252 | 0.030 |
Why?
|
| Narcotics | 1 | 2014 | 65 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 2019 | 665 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 238 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1737 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 782 | 0.020 |
Why?
|
| Health Status | 1 | 2014 | 429 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1582 | 0.020 |
Why?
|
| Stents | 1 | 2015 | 657 | 0.020 |
Why?
|
| Anxiety | 1 | 2014 | 422 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 3256 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 498 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 2264 | 0.020 |
Why?
|
| Depression | 1 | 2014 | 942 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 8903 | 0.020 |
Why?
|